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There is new and growing experience with venovenous extracorporeal life support (VV 
ECLS) for neonatal and pediatric patients with single-ventricle physiology and acute 
respiratory distress syndrome (ARDS). Outcomes in this population have been defined 
but could be improved; survival rates in single-ventricle patients on VV ECLS for respi-
ratory failure are slightly higher than those in single-ventricle patients on venoarterial 
ECLS for cardiac failure (48 vs. 32–43%), but are lower than in patients with biventricular 
anatomy (58–74%). To that end, special consideration is necessary for patients with 
single-ventricle physiology who require VV ECLS for ARDS. Specifically, ARDS disrupts 
the balance between pulmonary and systemic blood flow through dynamic alterations 
in cardiopulmonary mechanics. This complexity impacts how to run the VV ECLS circuit 
and the transition back to conventional support. Furthermore, these patients have a 
complicated coagulation profile. Both venous and arterial thrombi carry marked risk 
in single-ventricle patients due to the vulnerability of the pulmonary, coronary, and 
cerebral circulations. Finally, single-ventricle palliation requires the preservation of low 
resistance across the pulmonary circulation, unobstructed venous return, and optimal 
cardiac performance including valve function. As such, the proper timing as well as the 
particular conduct of ECLS might differ between this population and patients without 
single-ventricle physiology. The goal of this review is to summarize the current state of 
knowledge of VV ECLS in the single-ventricle population in the context of these special 
considerations.
Keywords: venovenous extracorporeal life support, extracorporeal membrane oxygenation, single ventricle, 
congenital heart disease, acute respiratory distress syndrome, cannulation, thrombosis, anticoagulation
iNTRODUCTiON
Extracorporeal life support (ECLS) has been used in patients with severe cardiopulmonary fail-
ure for 40 years (1, 2). In the 1970s, pioneering clinicians adapted ECLS from cardiopulmonary 
bypass used in the operating room as a treatment for respiratory failure that was unresponsive to 
conventional therapy in the intensive care unit (3). Contemporaneous studies showed a survival 
benefit from ECLS in neonatal but not adult populations with severe respiratory failure (4, 5). In 
neonatal patients, ECLS interrupted the pathophysiologic cycle of hypoxia, acidosis, and pulmonary 
hypertension (2). However, with improvements in patient selection and technology, along with 
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the more recent CESAR trial that showed a survival benefit in 
adult patients randomized to receive care in ECLS centers, ECLS 
has now become an important therapeutic option for adults 
with acute respiratory distress syndrome (ARDS) as well (2, 6). 
Likewise, based on experience drawn from these two populations 
and a growing body of research, ECLS for pediatric ARDS has 
also been demonstrated to be a viable treatment alternative to 
conventional therapy (7, 8).
Extracorporeal life support for cardiac failure has simultane-
ously evolved in each of these patient populations. In all ages, 
survival is less than in patients on ECLS for respiratory failure, 
but has improved over time (9).1
Regardless of the indication, whether cardiac, respiratory, or 
cardiorespiratory failure, ECLS was conducted through venous 
and arterial cannulation [venoarterial (VA) ECLS] when it was 
first introduced into clinical practice. Progressively, experience 
increased with venovenous (VV) cannulation for patients with 
respiratory failure but preserved cardiac function. Initially, this 
strategy required two separate cannula be placed in two large 
veins (e.g., bilateral femoral venous cannulation). Today, most 
VV ECLS can be performed using single site cannulation with a 
dual-lumen catheter.
Single-ventricle patients with ARDS supported with VV 
ECLS exist at an interesting intersection of these experiences. 
They have significant cardiac disease, but require ECLS for a pri-
mary respiratory indication. The population spans the neonatal 
and pediatric age groups, and increasingly will include adults. 
Cannulation strategies must account for an anatomic spectrum 
between patients and changes that will occur within individuals 
as they progress through surgical palliation of their heart disease. 
This review explores the prevailing physiologic considerations 
relevant to this challenging patient population in the context of 
the published literature.
eCLS iN ReSPiRATORY FAiLURe
The use of ECLS for respiratory failure in the pediatric population 
remained relatively stable until the Influenza A H1N1 outbreak in 
2009 after which its use has increased each year (8–11). In neonates, 
ECLS peaked in 1992 and then decreased in large part related to 
the introduction of inhaled nitric oxide to clinical practice (8)1. 
In both neonatal and pediatric patients, survival has not changed 
significantly in recent years (74% neonatal survival, 58% pediatric 
survival)1. However, the trend is toward placing more complex 
and sicker patients on ECLS. For example, pediatric patients 
placed on ECLS with a comorbid condition increased from 19% 
in 1993 up to 47% in 2007 with a 20% increase in survival of these 
patients (11). Factors associated with mortality in patients with 
respiratory failure on ECLS include diagnosis (pertussis, ARDS 
related to sepsis, fungal pneumonia, congenital diaphragmatic 
hernia), comorbid conditions (liver failure, cancer, renal failure, 
cardiac arrest), duration of ventilation prior to initiation of ECLS, 
and pre-ECLS pH (10, 11). Some studies but not all have found 
1 ECLS Registry Report. International Summary. Extracorporeal Life Support 
Organization. http://www.elso.org/Registry/Statistics.aspx. Accessed April 2016.
VV ECLS to have a lower mortality that VA ECLS in respiratory 
failure patients (8, 11, 12).
eCLS iN THe SiNGLe-veNTRiCLe 
POPULATiON
Extracorporeal life support was first used in patients with 
single-ventricle physiology who experienced difficulty separating 
from cardiopulmonary bypass in the operating room. This was 
described in a 1996 outcome analysis of a single center’s experi-
ence with patients undergoing surgery for congenital heart dis-
ease placed on VA ECLS. Initial survival estimates were between 
17 and 25% depending on the stage of palliation (13). Since that 
time, the description of VA ECLS in single-ventricle patients has 
evolved and become further refined. Numerous outcome studies 
have reported a wide range of survival depending on the year 
of study, institution, underlying anatomy, and stage of palliation 
(14–26). The most recent estimates suggest a survival of 32–43% 
with later stages of palliation having higher mortality (27, 28).
vA vS. vv eCLS
Historically, all single-ventricle patients in need of more than 
conventional therapy were placed on VA ECLS regardless of 
indication. As technology and expertise grew in the area of VV 
ECLS for ARDS, it became a consideration for the unique single-
ventricle population with respiratory failure and adequate cardiac 
function. There are several potential benefits to VV compared to 
VA ECLS in this population, but also challenges. First, in VV 
ECLS, fully oxygenated blood from the circuit augments the 
oxygen content of blood delivered to the lung, which may coun-
teract the increased pulmonary vascular resistance (PVR) that 
can occur in ARDS (29, 30). In single-ventricle patients, potential 
differences in pulmonary oxygen content between VA and VV 
ECLS depend on the stage of palliation and cannula position. 
Clinicians must consider these potential differences since second 
and third stage palliation results in passive pulmonary blood flow, 
and preserving a low PVR may be particularly important. Second, 
because ventricular ejection provides all systemic blood flow in 
VV ECLS, pulsatile flow is preserved. Non-pulsatile flow has been 
shown to increase catecholamine release, which may impair flow 
through the microcirculation, increase myocardial work through 
increased systemic afterload, and decrease end-organ perfusion 
(29, 31). Third, VV ECLS might decrease the risk of stroke if blood 
from the circuit can be returned exclusively to the pulmonary 
circulation (29, 30). However, in single-ventricle patients, this 
situation is uncommon, occurring only in Glenn patients if the 
inflow cannula (for multisite VV ECLS) is placed in the SVC, in 
Glenn patients if a dual-lumen single cannula is placed in the SVC, 
and in patients with an unfenestrated Fontan. Thus in general, 
VV ECLS does not afford the usual advantage over VA ECLS of 
decreased stroke risk in single-ventricle physiology. Finally, VV 
ECLS flow rates should not directly impact the ratio of pulmonary 
to systemic blood flow (Qp:Qs). Thus, like all VV ECLS, pump 
flow can be titrated based on the percentage of cardiac output 
necessary to provide adequate oxygenation and ventilation for 
TABLe 1 | Summary of vv eCLS in single-ventricle patients reported in the literature.
Study Year(s) N with single-
ventricle anatomy 
placed on vv eCLS
Single-
ventricle  
patient  
diagnosis
Stage of palliation  
Percent (n)
indication  
Percent (n)
Cannulation  
Percent (n)
Survival  
Percent (n)
Complications 
Percent (n)
Booth 
et al. (18) 
1984–
2002
1 DILV BDG Post-operative 
cyanosis
Right IJ and CA No Death
1
In full cohort:  
n = 20 (2 VV and 18 
VA ECLS SV patients)
Hypoplastic RV Fontan RSV pneumonia Right FV Yes
In full cohort: 
40% (8)
Developed sepsis, 
required conversion 
to VA ECLS
Imamura 
et al. (30)
1997–
2003
9 •	 4 HLHS
•	 2 PA/IVS
•	 3 TA
In full cohort: 
•	 47% (8) Systemic to 
pulmonary shunt
•	 18% (3) Other 
surgery
•	 35% (6) No surgery
In full cohort:
•	 41% (7) Acute 
viral pneumonia
•	 59% (10) Acute 
severe hypoxia
In full cohort:
•	 82% (14) RA/CA 
via right IJ
•	 18% (3) RA/CA 
via transthoracic 
approach
In full cohort:
88% (15)
In full cohort:  
59% (10) required 
surgical intervention 
to wean from VV 
ECLS support
In full cohort: 
n = 17 (9 SV and 8 
biventricular patients 
on VV ECLS)
Ryan et al. 
(32)
2010 1 HLHS BDG Post-operative 
cyanosis
CA via transthoracic 
approach
Yes None
Jolley 
et al. (33)
1999–
2012
4 ND BDG ND ND 100% (4) ND
In full cohort:  
n = 103 (4 VV and 99 
VA ECLS SV patients)
In full cohort: 
41% (42)
Aydin 
et al. (29)
1990–
2012
89 •	 22 HLHS
•	 67 Other 
SV
•	 14% (13) No 
surgery
•	 61% (54) Shunt 
physiology
•	 25% (22) Classic 
Glenn, BDG, Fontan
•	 34% (30) 
Cardiac
•	 66% (59) 
Respiratory
•	 9% (8) Other
All sites included 
for patients 
with multisite 
cannulation
•	 64% (57) IJ
•	 27% (24) RA/CA
•	 11% (10) FV
48% (43) Most common:
•	 25% (22) Surgical 
bleeding
•	 42% (37) Renal 
injury
•	 47% (42) Cardiac 
support with 
inotropes
BDG, bidirectional Glenn; CA, common atrium; DILV, double inlet left ventricle; FV, femoral vein; HLHS, hypoplastic left-heart syndrome; IJ, internal jugular vein; ND, not described in 
the publication; PA/IVS, pulmonary atresia with intact ventricular septum; RA, right atrium; RSV, respiratory syncytial virus; RV, right ventricle; SV, single ventricle; TA, tricuspid atresia. 
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any given amount of recirculation. Conversely, in VA ECLS in 
order to maintain adequate systemic oxygen delivery, flow must 
increase in a manner proportional to the Qp:Qs. Indeed, depend-
ing on the native ventricular function, anatomy, cannula size, and 
cannula position, VA ECLS could result in a marked increase in 
pulmonary blood flow that could aggravate the underlying lung 
injury. Likewise, higher ECLS flow rates could result in more 
inflammation, hemolysis, and autoantibody formation (29). 
Several of these points will be discussed in further detail below.
vv eCLS iN SiNGLe-veNTRiCLe 
PATieNTS
The limited experience of VV ECLS in the single-ventricle 
population is summarized in Table 1 (18, 29, 30, 32, 33). Booth 
and colleagues (18) were the first to describe the use of VV ECLS 
in single-ventricle patients in 2004. In a retrospective report, they 
described a cohort of 20 single-ventricle patients with cavopul-
monary connections supported on ECLS. Their cohort included 
two patients placed on VV ECLS for respiratory indications, one 
following bidirectional Glenn surgery who did not survive and one 
following Fontan surgery who required conversion to VA ECLS due 
to the development of sepsis and hemodynamic instability (18).
Imamura and colleagues (30) reported a case series later that 
year of 17 patients with cyanotic heart disease placed on VV ECLS 
for either acute hypoxia or pneumonia. Nine of these patients had 
single-ventricle anatomy. The full cohort had a high survival rate 
with only two mortalities due to late sepsis after decannulation. 
Fifty-nine percent of these patients required a surgical procedure 
to wean off ECLS (30).
Six years later, Ryan and colleagues (32) described a patient 
following bidirectional Glenn surgery who survived VV ECLS. 
This patient was prenatally diagnosed with hypoplastic left-heart 
syndrome (mitral atresia and aortic atresia), a restrictive atrial sep-
tum, and aortic arch hypoplasia. He had an uncomplicated course 
through his bidirectional Glenn procedure after which he devel-
oped refractory hypoxemia despite normal ventricular function, 
low transpulmonary pressures, and low atrial pressures. He was 
supported for 7 days on VV ECLS with improvement in his arterial 
saturations and no significant change to his pulmonary pressures 
or cardiac function on subsequent cardiac  catheterization (32).
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Aydin and colleagues (29) provided the most detailed 
description to date of VV ECLS in single-ventricle patients. 
Using data reported to the Extracorporeal Life Support 
Organization (ELSO) from 1990 to 2012, they described 89 
single-ventricle patients at various stages of surgical pallia-
tion placed on VV ECLS. Their cohort had a 48% survival to 
discharge with duration of intubation before initiation of ECLS, 
mean airway pressure and partial pressure of carbon dioxide 
prior to cannulation, and renal injury all associated with 
mortality (29). While this is the largest published report in this 
patient population and suggests that VV ECLS is a viable option 
in single-ventricle physiology, there are questions that could 
not be answered by these data. Specifically, 34% of patients 
in this cohort were placed on VV ECLS for “cardiac reasons”. 
Because this is a descriptive retrospective registry report, the 
authors could not provide more details about this group of 
patients. VV ECLS does not directly support cardiac function, 
and, thus, it is unknown whether there are clinically important 
distinctions between patients identified as needing support 
for cardiac vs. respiratory indications, or if these distinctions 
are due to vagaries in patient coding (29, 34, 35). There is also 
no information on the timing of ECLS in relation to surgery. 
Presumably there are significant differences between patients 
supported with ECLS in the immediate post-operative period 
and those placed on ECLS much longer after surgery (29, 35). 
Finally, there are no data on the rate of conversion from VV to 
VA ECLS in this cohort, an important outcome when consider-
ing an ECLS approach in these patients (29, 34).
SPeCiAL CONSiDeRATiONS iN  
SiNGLe-veNTRiCLe ARDS PATieNTS ON 
vv eCLS
Timing of Cannulation
Though the use of mechanical ventilation in ARDS is potentially 
lifesaving, the associated cyclic regional over-distention and alve-
olar collapse, along with toxicity from the high-inspired oxygen 
that is necessary to compensate for impaired gas exchange can 
all worsen the underlying lung injury. Though lung-protective 
ventilation can mitigate ventilator-associated lung injury and 
oxygen toxicity, these forces are still present and mortality in 
ARDS using conservative strategies is significant (6, 36). ECLS 
has the potential to greatly reduce if not eliminate these factors. 
The proper timing of ECLS remains a difficult clinical dilemma, 
which must balance consideration of the potential benefit of lung 
rest afforded by ECLS against its associated morbidities.
Multiple observational adult studies have found outcomes to 
be associated with duration of mechanical ventilation prior to 
initiation of ECLS in patients with ARDS (37–40). For example, 
Pranikoff and colleagues (37) found that survival in adults with 
ARDS was inversely associated with the number of pre-ECLS 
mechanical ventilation days and a 50% mortality at 5  days of 
mechanical ventilation. Beiderlinden and colleagues (38) found 
the average number of pre-ECLS mechanically ventilated days 
to be 5.3 in survivors as compared to 8.7 in non-survivors. The 
current adult ARDS recommendations suggest that patients 
mechanically ventilated for more than 7 days may be less likely to 
benefit from ECLS for respiratory failure (2, 36).2
Zabrocki and colleagues (11) evaluated this question in the 
pediatric ARDS population. They found that patients ventilated 
for ≤14 days had similar survivals between 56 and 61%, while 
those that were ventilated >14 days significantly dropped their 
survival to 38%. Of note, the group of patients ventilated between 
>7 and 14 days had lower but not significantly lower survival than 
those ventilated 0–7  days, so there may be important survival 
differences that were not able to be differentiated in this study. 
Indeed, Nance and colleagues (41) reported a statistically signifi-
cant survival decrease of 2.9% for each pre-ECLS ventilator day 
(41). As such, the most current ELSO guidelines for pediatrics 
suggest that consideration of ECLS is best within the first 7 days 
of mechanical ventilation at high levels of support (2, 11).3 At this 
point, a clear consensus is lacking on the proper timing of VV 
ECLS in patients with respiratory failure.
In the single-ventricle VV ECLS population, Aydin and col-
leagues (29) showed that a shorter duration of intubation prior to 
initiation of VV ECLS was associated with mortality. Specifically, 
they found the median duration of intubation prior to ECLS 
in survivors to be 24  h as compared to 76  h in non-survivors 
(p-value = 0.004) with an odds ratio on multivariate analysis of 
mortality to be 1.01 (95% CI 1.003–1.016, p-value = 0.003) (29). 
Important physiology underlies the question of timing of cannula-
tion in the single-ventricle patient. As mentioned, these patients 
rely on a low PVR and transpulmonary gradient at later stages 
of palliation. Pulmonary vascular dysfunction is known to occur 
in patients with ARDS (42). Furthermore, elevations in PVR and 
transpulmonary gradient have been shown to be independent 
predictors of mortality in ARDS, even in patients without heart 
disease (42). Not only is elevated PVR a common occurrence, but 
also PVR tends to drop in survivors and remains elevated in non-
survivors (43). Mechanistically, endothelial injury resulting in 
inflammation, thrombosis, increased vascular tone due to hypoxic 
pulmonary vasoconstriction and an imbalance of vascular media-
tors, and pulmonary vascular remodeling with intimal fibrosis are 
all key in the elevation of PVR (44, 45). The consequences of these 
changes could be devastating for patients awaiting palliation with 
cavopulmonary connections as well as those already dependent 
on passive pulmonary blood flow. Thus, although clinical evidence 
is lacking, there is sound rationale for ECLS in patients with 
single-ventricle physiology and ARDS, perhaps even very early in 
the course of illness. Further research is required to conclusively 
demonstrate the proper timing of ECLS in these patients.
Cannula Type and Location
The experience with cannula placement continues to evolve in 
VV ECLS. The most comprehensive review of cannula type in 
the overall VV ECLS pediatric population came from Zamora 
2 ELSO Guidelines for Adult Respiratory Failure v1.3. Extracorporeal Life Support 
Organization. http://www.elso.org/resources/Guidelines.aspx. Accessed April 
2016.
3 ELSO Guidelines for Pediatric Respiratory Failure v1.3. Extracorporeal Life 
Support Organization. http://www.elso.org/resources/Guidelines.aspx. Accessed 
April 2016.
TABLe 2 | Cannula type and location in vv eCLS single-ventricle patients (29).
Survivors  
(n = 46)
Non-survivors  
(n = 43)
p-value
Cannula type Venovenous double lumen (VVDL) 27 (59%) 30 (70%) 0.28
Venovenous (VV) not otherwise specified 17 (37%) 10 (23%) 0.15
Venovenous double lumen with additional single-lumen venous 
cannula (VVDL-V)
2 (4%) 3 (7%) 0.53
Survivors 
 (n = 46 patients,  
51 cannulations)*
Non-survivors 
(n = 43 patients,  
48 cannulations)*
p-value
Cannulation 
location
Jugular vein 30 (59%) 27 (56%) 0.76
Right atrium 12 (23%) 12 (25%) 0.82
Femoral vein 5 (10%) 5 (11%) 0.87
Other 4 (8%) 4 (8%) 1
*Percentage based on number of cannulations.
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and colleagues (46). Using the ELSO database, they compared 
single dual-lumen venovenous cannulas (VVDL) and multisite 
venovenous (VVMS) cannulation. Over the 14-year cohort, they 
found similar overall utilization of VVDL and VVMS though the 
annual use of VVDL was increasing, reaching 71% of all cannulas 
in 2011. VVDL strategies were able to achieve higher flow rates 
overall. Survival was similar between the two groups and they 
found no difference in outcomes between wire-reinforced and 
non-wire-reinforced cannulas. Importantly, mechanical and 
cardiovascular complications were higher in patients with VVDL 
cannula (46). The higher incidence of cardiovascular complica-
tions is a potential concern in single-ventricle patients who tend 
to have more fragile hemodynamics.
Indeed, cannula type and location are a particular challenge in 
single-ventricle patients. In patients at the first stage of palliation 
with a Sano shunt, special care should be taken so that cannula 
placement does not mechanically interfere with flow through the 
shunt. In addition, for all patients at the first stage of palliation, it 
is critical to consider that unobstructed SVC flow is necessary for 
second-stage palliation with a Glenn (superior cavopulmonary 
connection) and unobstructed IVC flow is necessary for third-
stage palliation with a Fontan (total cavopulmonary connection). 
As such, the ramifications of vascular injury or occlusive thrombus 
are far graver in these patients than in patients with biventricular 
physiology. Furthermore, for patients at these stages of pallia-
tion, it is important to ensure that the superior and inferior caval 
circulations have sufficient cerebral and lower body drainage and 
perfusion. Inability to maintain adequate drainage and perfusion 
has been attributed to worse outcomes in this population (18, 33).
According to Aydin and colleagues (29), in the single-ventricle 
VV ECLS population, VVDL was used in 70% of patients with 
the internal jugular vein being the most common cannulation 
site (64%). The most common cannula approaches based on 
anatomy were (1) VVDL placed in the right internal jugular vein 
for unrepaired single-ventricle patients or those with a central or 
Sano shunts, (2) VVMS in the right internal jugular and femoral 
vein for those with a classic or bidirectional Glenn shunt, and (3) 
VVMS in the right internal jugular and femoral vein in patients 
with a Fontan. Importantly, there was no association with mortal-
ity between cannula types and cannula sites (29). Cannulation 
sites in all VV ECLS single-ventricle studies are included in 
Table 1. Breakdown of cannula type and location according to 
Aydin and colleagues (29) is shown in Table 2.
The proper cannulation strategy for single-ventricle patients 
at particular stages of palliation remains a critical unanswered 
question that requires more study with both short- and long-term 
outcome measures. In the absence of guiding data, careful case-
specific consideration is required that accounts for the particular 
anatomy, ECLS flow requirements, and future surgical procedures 
in order to make the best determination of the risks and benefits 
of any given cannulation strategy. Furthermore, since patients 
with single-ventricle physiology have limited physiologic reserve 
and techniques used to measure cardiac function have limita-
tions, clinicians must be prepared to transition to VA ECLS after 
embarking on a VV strategy as the initial approach if the clinical 
response is inadequate.
Bleeding, Thrombosis, and 
Anticoagulation
In general, patients with single ventricles need special considera-
tion in regard to coagulation. These patients are at risk for throm-
bosis perioperatively related to their surgery and post-surgical 
management. They are also at risk between stages of palliation 
due to interference with laminar flow caused by altered anatomy, 
potential cardiac dysfunction, and the introduction of shunts, 
sutures, and other thrombogenic artificial material that creates an 
environment suitable for thrombus formation (47). Procoagulant 
and anticoagulant abnormalities have been found in patients at 
all stages of palliation. Preoperatively, patients tend to have low 
levels of procoagulants and anticoagulants with different studies 
relating these deficiencies to oxygen saturation and ventricular 
dysfunction (48, 49). Interestingly, these patients do not seem to 
be predisposed to bleeding, suggesting that their factor and protein 
suppression maintains hemostatic balance (47). Post-operatively, 
both Glenn and Fontan patients transiently develop coagulopathy 
related to hemodynamic changes and liver dysfunction (50). 
Abnormal hemodynamics in the absence of a ventricular chamber 
dedicated to pumping venous return into the pulmonary vascular 
bed may predispose patients to subclinical hepatic dysfunction, 
leading to selective disturbances of protein synthesis.
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While the clinical significance of these coagulation 
 abnormalities is not directly known, the epidemiologic data 
suggest that single-ventricle patients have a predisposition for 
thrombosis. Manlhiot and colleagues (47) reported thrombotic 
risk after all three stages of palliation. The highest risk comes 
after the first stage of palliation with thrombotic complications 
occurring in 40% of patients. An important component of these 
thrombotic complications is Blalock–Taussig shunt thrombus 
formation, which has a reported incidence of 1–17%. Following 
the second stage of palliation, thrombotic complications occur in 
28% of patients. The 5-year freedom of thrombotic complications 
was 79% in Fontan patients. Of note, thrombotic complications 
were associated with increased mortality after all stages (47).
Extracorporeal life support only adds to the complicated hemo-
static picture in this patient population. Bleeding and thrombosis 
are common complications in ECLS with one or both seen on 
86% of autopsies done after ECLS-related mortality (51). Based 
on the ELSO registry between 2005 and 2011, clinical bleeding 
complications occurred in 38% of patients, while thrombosis was 
noted in 31% of patients on ECLS. Furthermore, survival was 
decreased by 40% when a bleeding complication occurred and by 
33% when a thrombotic complication occurred. Factors associ-
ated with bleeding and thrombosis included longer duration of 
ECLS and use of VA cannulation (52). Specifically, in pediatric 
cardiac surgery patients on ECLS, hemorrhagic complications 
occurred in 57% of patients and their mortality was higher than 
those without (53). ECLS is also known to be associated with 
increased odds of thrombus formation in this population (54).
Aydin and colleagues (29) retrospectively addressed this 
question in the VV ECLS single-ventricle population. They found 
thrombus related to the ECLS circuit in 18% of patients, surgical 
bleeding in 25% of patients, and hemolysis in 5% of patients. 
There was no difference in incidence between survivors and non-
survivors (29). Interestingly, these initial data suggest a lower risk 
of bleeding and thrombotic complications than is seen in both the 
pediatric cardiac surgery patients on ECLS and in the broader 
ECLS population. More studies are required to better understand 
these differences.
In sum, single-ventricle patients have a physiology that 
 supports a predisposition to thrombus formation, abnormal 
coagulation profiles, and a higher observed incidence of throm-
bus and bleeding. The risks of bleeding and thrombosis associ-
ated with ECLS contribute to the already complex coagulation 
considerations in the single-ventricle patient.
vv eCLS Flows in Single-ventricle Patients
Patients with aortopulmonary shunts require high flows on VA 
ECLS because of pulmonary runoff. Supporting higher flows can 
be achieved with large cannula or multiple cannulation sites, but 
may be technically difficult to achieve as these patients are usually 
infants and may have abnormal, stenotic, or thrombosed vascu-
lature. Strategies to control pulmonary blood flow can include 
medical interventions, such as high positive end-expiratory pres-
sure (PEEP), low-inspired oxygen, and permissive hypercapnia. 
Surgical interventions include restriction of the shunt with a clip 
or ligature (26). Full occlusion of the shunt to prevent pulmonary 
run off has been described and found to be associated with poor 
survival (15, 26). In addition, there is a potential risk for the arte-
rial cannula to enter or occlude a shunt. The use of VV ECLS when 
cardiac function is adequate decreases the risk for over-circulation 
in turn obviating the need for these medical or surgical strategies 
to limit pulmonary blood flow and their potential complications. 
Furthermore, lower flows decrease patient exposure to blood 
products, lessen hemolysis risk, and reduce the activation of 
inflammation by decreasing blood contact with the ECLS circuit.
Lung Rest Settings
Data are lacking across patient populations on ideal mechanical 
ventilator settings for patients on ECLS (55, 56). In fact, in some 
patient populations (e.g., patients awaiting lung transplantation) 
extubation while on ECLS is an emerging management strategy 
(55, 57). Although VV ECLS can replace lung function, this 
depends upon the efficiency of ECLS, which relates to the maxi-
mum achievable flow and the extent of recirculation. Therefore, 
at times some ventilator support might be required to augment 
ventilation and/or oxygenation (55). Beyond these considera-
tions, important questions remain unanswered regarding ideal 
lung rest ventilator settings (58). For example, what is the ideal 
physiology for lung recovery? In general, based on published 
ECLS trials (that described but did not study ventilator settings) 
higher levels of PEEP, lower inspired oxygen, low tidal volumes, 
lower peak and plateau pressures, and lower rates appear to be 
common practice (54, 56, 59, 60). The single-ventricle population 
raises further questions. In patients at the first stage of palliation, 
it might be most appropriate to manage the ventilator in a man-
ner that avoids increasing the Qp:Qs. In patients at the second 
and third stage of palliation (i.e., Glenn and Fontan), the impact 
of pulmonary venous return on cardiac output is an important 
factor in the ventilator management. Further study is needed to 
optimize this aspect of management.
weaning Off of eCLS
Similar to ideal lung rest settings, a standard process for weaning 
off of ECLS is lacking. Trials off of VV ECLS are far simpler than 
trials off of VA ECLS, since clinicians can simply stop delivering 
sweep gas through the oxygenator without disconnecting the 
patient from the ECLS circuit (58). Conversely, weaning from VA 
ECLS requires reduction in circuit flow and the introduction of 
a bypass bridge if a trial off all flow is desired. For patients with 
single-ventricle physiology, clinicians must carefully consider the 
respiratory and circulatory status of the lung in order to ensure 
that the benefit of ECLS has been fully leveraged. Readiness for 
separation from ECLS differs fundamentally between single-
ventricle patients and most patients supported with ECLS for 
respiratory failure. Impaired cardiopulmonary interactions are 
poorly tolerated in these patients, requiring careful scrutiny of 
the adequacy of systemic oxygen delivery during the transition 
from lung rest settings to full ventilation. Given the challenges 
associated with cannulation in these patients, reinstituting ECLS 
after decannulation would be expected to be difficult or not pos-
sible. As such, longer weaning trials (off of sweep gas flow prior 
to decannulation) may be wise.
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CONCLUSiON
Based on growing experience, VV ECLS to support the single-
ventricle patient with ARDS is a viable option when conventional 
therapy fails or is associated with significant morbidity. Outcomes 
are within the scope of ECLS outcomes in other patient popula-
tions. Special thought is necessary given the unique single-ventri-
cle physiology, including cannulation, hemorrhagic, thrombotic, 
circuit flow, and lung rest considerations. In addition, more study 
is necessary to further understand and enhance the management 
of these patients.
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